Ratings by Cantor Fitzgerald (Josh Schimmer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/29/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/26/2026 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2026 | GH Research PLC | GHRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Trevi Therapeutics | TRVI | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2026 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Nuvalent | NUVL | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/22/2026 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/9/2026 | Krystal Biotech | KRYS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/8/2026 | Compass Pathways | CMPS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/5/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/31/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/21/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Trevi Therapeutics | TRVI | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Overweight (N/A) |
5.42 (6.28) |
15.87% | Details | |
| 11/11/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/10/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/6/2025 | Invivyd Inc. | IVVD | New Coverage | Overweight (N/A) |
1.16 (0.93) |
-19.83% | Details | |
| 9/26/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/24/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/23/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/10/2025 | GH Research PLC | GHRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/8/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/21/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/29/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Krystal Biotech | KRYS | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/23/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/3/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/1/2025 | Trevi Therapeutics | TRVI | New Coverage | Overweight (N/A) |
5.47 (17.38) |
217.73% | Details | |
| 6/13/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/4/2025 | GH Research PLC | GHRS | New Coverage | Overweight (N/A) |
12.08 (23.61) |
95.45% | Details | |
| 5/16/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | CG Oncology | CGON | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | Tourmaline Bio | TRML | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2025 | Denali Therapeutics Inc. | DNLI | Upgrade | Overweight (Neutral) |
12.86 (24.77) |
92.61% | Details | |
| 4/1/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2025 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Overweight (N/A) |
10.13 (4.23) |
-58.24% | Details | |
| 3/6/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/7/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/3/2024 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Septerna Inc | SEPN | New Coverage | Overweight (N/A) |
23.55 (36.57) |
55.29% | Details | |
| 10/14/2024 | Longboard Pharmaceuticals Inc | LBPH | Downgrade | Neutral (Overweight) |
38.90 (59.98) |
54.19% | Details | |
| 10/7/2024 | Denali Therapeutics Inc. | DNLI | Downgrade | Neutral (Overweight) |
28.63 (24.77) |
-13.48% | Details | |
| 8/19/2024 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Overweight (N/A) |
13.33 (10.28) |
-22.88% | Details | |
| 8/13/2024 | Artiva Biotherapeutics | ARTV | New Coverage | Overweight (N/A) |
11.22 (9.80) |
-12.66% | Details | |
| 7/1/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Zura Bio Ltd. | ZURA | New Coverage | Overweight (N/A) |
3.83 (4.31) |
12.53% | Details | |
| 3/20/2024 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
38.81 (14.91) |
-61.58% | Details | |
| 3/11/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
47.93 (65.73) |
37.14% | Details | |
| 11/15/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Neurocrine Bio. | NBIX | New Coverage | Overweight (N/A) |
107.91 (161.44) |
49.61% | Details | |
| 10/24/2023 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
28.26 (35.91) |
27.07% | Details | |
| 10/24/2023 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
18.70 (24.77) |
32.46% | Details | |
| 10/24/2023 | Krystal Biotech | KRYS | New Coverage | Overweight (N/A) |
108.96 (340.21) |
212.23% | Details |
